PrecisCa
Avatar

Heme Tumor Board: 78 y/o Male With Newly Diagnosed Monoclonal Gammopathy of Renal Significance Presenting for Second Opinion

By PrecisCa FEATURING Daniel Pollyea, Ajay Nooka, Peter Forsberg, David Schuster
By PrecisCa FEATURING Daniel Pollyea, Ajay Nooka, Peter Forsberg, David Schuster
0 views
December 15, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Recommended

AUTOPLAY
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
15:36
Memorial Sloan Kettering Cancer Center

Key Myeloma & MGUS Updates From ASH

Feat. S. Mailankody
41:54
University of Colorado Division of Hematology

Overview of Pathophysiology, Diagnosis and Management of Multiple My…

Feat. K. Sidor
10:23
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "iStopMM Study - Revised Definition of Free …

Feat. T. Einarsson Long
19:35
Dana-Farber Cancer Institute

Updates in the Management of SMM/MGUS and the Prevention of Progress…

Feat. Y. Liu
26:58
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Updates on Myeloma Precursor Diseases and AL Amyloidosis

Feat. S. Susanibar-Adaniya
27:06
Moffitt Cancer Center

Hot Off the Press: Experts Discuss the Latest Data in Plasma Cell Dy…

Feat. R. Baz, M. Alsina, K. Shain, A. Grajales-Cruz
20:28
Dana-Farber Cancer Institute

The PROMISE of Early Detection and Interception in Myeloma

Feat. I. Ghobrial
44:53
MyCancerHaven

Experts Discuss MGUS and Smoldering Myeloma

Feat. R. Vij, P. Kapoor
12:32
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Early Benefits and Psychological Effects of…

Feat. S. Rögnvaldsson
41:46
Yale Cancer Center

Early Detection and Interception in Myeloma: The PROMISE Study

Feat. I. Ghobrial
23:42
GRACE

Multiple Myeloma & Cellular Therapies: A Patient-Centric Primer

Feat. S. Rajeeve
10:03
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "MGUS and the Risk of Thrombotic Events - Re…

Feat. S. Rögnvaldsson
22:16
SOHO Italy 1st School of Multiple Myeloma

Molecular Pathogenesis of MM: MGUS and SMM, Genomic Complexity of th…

Feat. N. Bolli
20:17
Indy Hematology Review

Therapy for Newly Diagnosed Myeloma - Role of Transplant and MRD, DA…

Feat. K. Anderson
22:20
SOHO Italy 1st School of Multiple Myeloma

Single-Cell Characterization of the BM Immune Microenvironment in MM…

Feat. C. Botta
16:11
Natalie Callander

MGUS: Risk Stratification and Therapeutic Options

19:12
SOHO Italy 1st School of Multiple Myeloma

1st/2nd Relapse in MM: Predictive Factors, EMD, Role of sFLC in MGUS…

Feat. U. Markovic
19:16
Memorial Sloan Kettering Cancer Center

Should Smoldering Myeloma Be Treated?

Feat. O. Landgren
16:38
SOHO Italy 1st School of Multiple Myeloma

Extracellular Vesicles in Myeloma: What Is Their Role in MGUS-to-MM …

Feat. A. Reale